Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis

详细信息    查看全文

• 作者：Anne-Claire Frin^a ; ¹ ; Jé ; rô ; me Filippi^a ; ¹ ; Gilles Boschetti^b ; Bernard Flourie^b ; Jocelyne Drai^c ; Patricia Ferrari^d ; Xavier Hebuterne^a ; Sté ; phane Nancey^b ; ^{stephane.nancey@chu-lyon.fr}
• 关键词：Fecal markers ; Response to infliximab ; Ulcerative colitis
• 刊名：Digestive and Liver Disease
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：49
• 期：1
• 页码：11-16
• 全文大小：783 K
• 卷排序：49

文摘

Fecal markers might predict the response to anti-TNFα in ulcerative colitis (UC).AimsTo compare the performance of fecal calprotectin (fCal), lactoferrin (fLact), M2-PK (fM2-PK), neopterin (fNeo), and zonulin (fZon) to predict the response to therapy in active UC patients.MethodsDisease activity from 31 consecutive patients with an active UC, treated with infliximab (IFX) was assessed by the Mayo score at baseline and at week 14 and by the partial Mayo score at W52 and stool samples collected for fecal marker measurements at W0, W2, and W14.ResultsAt W14, 19 patients (61%) were responders to IFX induction. The median levels of fCal, fLact and fM2-PK drop dramatically from baseline to W14 in clinical responders. At W2, fM2-PK, fLact and fCal levels predicted accurately the response to IFX induction. At W14, fLact, fCal, and fM2-PK were individually reliable markers to predict sustained response at W52. The performances of fNeo and fZon were weaker in this setting.ConclusionsThe performance of fM2-PK at W2 to predict response to induction therapy with IFX was superior to that of fLact and fCal, whereas monitoring fLact was the best tool to predict adequately the course of the disease at one year under maintenance IFX in UC.